Litman Gregory Wealth Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Litman Gregory Wealth Management’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$1.59K	Buy	+100	New	+$1.42K	﹤0.01%	308

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Litman Gregory Wealth Management's AUPH Position: Q4 2025 in Review

Litman Gregory Wealth Management opened a new position in Aurinia Pharmaceuticals (AUPH) in Q4 2025: 100 shares worth $1.59K. The stake represents ﹤0.01% of the portfolio and ranks #308 among its holdings.

255 funds tracked by Wall St. Rank hold AUPH as of Q4 2025.

Litman Gregory Wealth Management held 100 shares of Aurinia Pharmaceuticals worth $1.59K as of Q4 2025.
Aurinia Pharmaceuticals was a new Litman Gregory Wealth Management position in Q4 2025.
Aurinia Pharmaceuticals made up ﹤0.01% of Litman Gregory Wealth Management's portfolio in Q4 2025, its #308 holding.
255 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2025.

Based on Litman Gregory Wealth Management's 13F filing for Q4 2025, filed 12 Feb 2026.